Recent Updates
Recently added Catalysts

Measles, mumps, and rubella vaccine

Phase 3

Measles | Vaccine | Infectious Disease |GSK plc|Last Updated: Sep 26, 2016

Target and mechanism

ModalityVaccine

Also known as Measles vaccine, measles

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedUNCONTROLLED
Total Trials1
Total Enrollment -

FDA Designations

No designations recorded

Clinical trial landscape

Measles, mumps, and rubella vaccine · 2 trials · 4 indications

Phase 3 2
NCT00127010Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox DiseasesMeasles
COMPLETED- Analytics
NCT00127023Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox DiseasesMumps
COMPLETED944 Analytics
PHASE3COMPLETED
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
MeaslesUnlock trial analytics
PHASE3COMPLETED
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
MumpsUnlock trial analytics

Study Endpoints

Primary Endpoints

Antibody levels after vaccination
Antibody levels after vaccination.

Secondary Endpoints

Safety of the study vaccines
Safety of the study vaccines.
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposePREVENTION

Interventions

NameTypeDescription
Measles, Mumps, Rubella and Chickenpox (live vaccine)BIOLOGICAL -
Unlock Study Design Details

Eligibility Criteria

Age Range11 Months to 13 Months
SexALL
Healthy VolunteersYes
Study Sites48

Inclusion Criteria: * A male or female subject between 11-13 months of age (i.e. from 11 month birthday until the day before the 14 month birthday) at the time of the first vaccination. Exclusion Criteria: * History of previous measles, mumps, rubella and/or varicella vaccination or disease, or k...

Countries:BelgiumGermanyNetherlands
Unlock Eligibility Criteria

Frequently asked questions about Measles, mumps, and rubella vaccine

What is the measles, mumps, and rubella vaccine?

The measles, mumps, and rubella vaccine is a vaccine developed by GSK plc (ticker: GSK) to prevent measles, mumps, and rubella. It is also studied in combination with varicella (chickenpox) to protect against all four diseases. The vaccine is in Phase 3 clinical development and has been tested in healthy volunteers from 11 months of age.

What is the measles, mumps, and rubella vaccine used for?

The measles, mumps, and rubella vaccine is used to prevent measles, mumps, and rubella. Some formulations also include varicella, providing protection against chickenpox as well. It is intended for administration to healthy individuals, including infants from 11 months of age, to induce immunity against these viral infections.

Who makes the measles, mumps, and rubella vaccine?

The measles, mumps, and rubella vaccine is made by GSK plc, which trades under the ticker GSK. GSK is the developer of the combined vaccine candidates that include measles, mumps, rubella, and varicella components, and has conducted Phase 3 trials of these vaccines in Europe.

What phase is the measles, mumps, and rubella vaccine in?

The measles, mumps, and rubella vaccine is in Phase 3 clinical development. It has not been approved by the FDA for these indications. The Phase 3 trials have been completed, and the vaccine remains investigational.

What clinical trials is the measles, mumps, and rubella vaccine in?

The measles, mumps, and rubella vaccine has been evaluated in completed Phase 3 trials, including NCT00127023 and NCT00127010. NCT00127023 enrolled 944 healthy volunteers in Germany, while NCT00127010 was conducted in Belgium, Germany, and the Netherlands. Both trials studied combined vaccines to prevent measles, mumps, rubella, and chickenpox.